Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New wrinkle treatment combo shows promise in early trial

NCT ID NCT06834789

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested whether a new drug called AGN-151586 can be safely combined with BOTOX to treat moderate to severe frown lines between the eyebrows. Researchers monitored 132 healthy adults for side effects and immune responses after a single treatment session. The goal was to check safety and see if the combination works better than BOTOX alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

132 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has moderate or severe glabellar lines (GL) at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS). * Must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, 12-lead ECG parameters, clinical laboratory evaluations, and neurological assessment. Exclusion Criteria: * Active infection or dermatological condition at the treatment injection sites. * History of immunization to any botulinum neurotoxin serotype or hypersensitivity to any botulinum neurotoxin serotype or any other constituents of the study drug or its excipients, and/or other products in the same class.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glabellar lines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glabellar lines

Contacts and locations

Locations

  • Austin Institute for Clinical Research - Pflugerville /ID# 270834

    Pflugerville, Texas, 78660, United States

  • Eye Research Foundation /ID# 270827

    Newport Beach, California, 92663, United States

  • Investigate MD /ID# 270771

    Scottsdale, Arizona, 85260, United States

  • Marcus Facial Plastic Surgery /ID# 270770

    Redondo Beach, California, 90277, United States

  • Skin Research Institute LLC /ID# 270831

    Coral Gables, Florida, 33146-1837, United States

  • SkinDC /ID# 270932

    Arlington, Virginia, 22209, United States

  • Skincare Physicians /ID# 271018

    Chestnut Hill, Massachusetts, 02467, United States

  • Wilmington Dermatology Center /ID# 270828

    Wilmington, North Carolina, 28403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.